Thursday, January 23, 2025
No menu items!
No menu items!

CPFIS funds see 14.71% annual return in Q3, quarterly average return drops 2.54%

SINGAPORE: The Central Provident Fund Investment Scheme (CPFIS) funds showed strong performance in the third quarter of 2024, with an annual average return of 14.71%. This is up from 9.69% in the second quarter, according to the Investment Management Association of Singapore (IMAS) and Morningstar. However, the quarterly average return dropped to 2.54% in Q3, down from 3.11% in Q2.

Singapore Business Review reported that unit trusts had an annual return of 15.29%, with a quarterly return of 3.14%, while investment-linked products (ILPs) recorded an annual return of 14.33%, with a quarterly return of 2.14%.

Among CPFIS-included unit trusts, the EAA Fund Thailand Equity stood out with a quarterly return of 15.50%, followed by the EAA Fund China Equity (13.69%) and EAA Fund ASEAN Equity (12.10%). However, the EAA Fund Islamic Global Equity saw the largest drop, with a quarterly return of -4.68%.

In terms of annual average returns, the top performers included the EAA Fund US Large-Cap Growth Equity, which had a return of 32.75%, followed by the EAA Fund Sector Equity Biotechnology (27.18%) and EAA Fund US Large-Cap Blend Equity (27.13%).

Among ILPs, EAA Insurance China Equity led the average quarterly returns with a return of 12.58%, followed by the EAA Insurance Property – Indirect Global (9.87%), and EAA Insurance Global Equity Income (6.70%).

The worst-performing ILP categories included EAA Insurance Sector Equity Technology, EAA Insurance Islamic Global Equity, and EAA Insurance Islamic Equity – Other.

EAA Insurance Sector Equity Technology (34.44%) and EAA Insurance India Equity (28.33%) saw the best returns over 12 months. /TISG

Read also: Singapore’s CPF ranks 5th in the 2024 Mercer CFA Institute Global Pension Index

Hot this week

Sharon Osbourne regrets dramatic weight loss

Television personality Sharon Osbourne appeared on Piers Morgan’s show...

Brain Implant: Elon Musk’s Neuralink venture now ready for human trials

After controversial tests on monkeys, Elon Musk’s groundbreaking company,...

X users defending Emma Roberts over statement from Angelica Ross claiming she is transphobic 

The topic of transphobia is one of the utmost...
spot_img

Related Articles

Popular Categories

spot_imgspot_img